MedPath

Treatment of Indigestion by Unani medicine Jawarish Pudina Wilayati

Phase 3
Not yet recruiting
Conditions
Functional dyspepsia,
Registration Number
CTRI/2020/02/023637
Lead Sponsor
Central Council for Research in Unani Medicine CCRUM New Delhi
Brief Summary

This study is designed as a multicentric open trial in patients with **Su’ al-Hadm (Dyspepsia)****.** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be treated with Unani pharmacopoeial formulation **Jawarish Pudina Wilayati**5 gm twice daily with water for six weeks.  The patients will be assessed every second week. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be two years. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of****Jawarish Pudina Wilayati**

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / Scientific Name**

**Quantity**

|1.

Berg Sudab

*Ruta graveolens* Linn.

225 gm

|2.

Boora Armani

Aluminium Silicate

56 gm

|3.

Zanjabeel

*Zingiber officinale* Rosc.

230 gm

|4.

Zeera Safaid

*Cuminum cyminum*

185 gm

|5.

Zeera Siyah

*Carum carvi* Linn.

375 gm

|6.

Filfil Siyah

*Piper nigrum* Linn.

175 gm

|7.

Agar Hindi

Aquilaria agallocha fungus

7 gm

|8.

Ilaichi Khurd

*Elettaria cardamomum*Maton.

7 gm

|9.

Ilaichi Kalan

*Amomum subulatum* Roxb.

7 gm

|10.

Pudina Khushk

*Mentha arvensis* Linn*.*

7 gm

|11.

Taj Qalmi

*Cinnamomum tamala*

7 gm

|12.

Jaiphal

*Myristica fragrans*

7 gm

|13.

Qaranful

*Syzygium aromaticum*Linn.

7 gm

|14.

Anardana

*Punica granatum* Linn.

300 gm

|15.

Tamar Hindi

*Tamarindus indica* Linn.

300 gm

|16.

Maweez Munaqqa

*Vitis vinifera* Linn.

300 gm

|17.

Qand Safaid

Sugar

7.3 kg

|18.

Sirka Desi

Vinegar

450 ml

|19.

Sat Pudina

*Mentha arvensis* extract

10 gm

|20.

Sharbat Zanjabeel

*Zingiber officinale* Syrup

1.1 lit.

|21.

Aab Leemu

Lemon water

500 ml

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patients of either sex in the age group of 18-60 years 2.
  • Patients meeting the following Rome III diagnostic criteria for post prandial distress syndrome : Symptom onset greater than 6 months prior to the diagnosis, with the following criteria fulfilled for the past 3 months: 3.
  • No structural disease by upper endoscopy to explain the symptoms 4.
  • At least one of the following symptoms: a.
  • Bothersome postprandial fullness b.
  • Early satiation c.
  • Epigastric pain d.
  • Epigastric burning At least one of the following: 5.
  • Bothersome postprandial fullness after ordinary sized meals occurring at least several times a week 6.
  • Early satiation that prevents finishing a regular meal at least several times a week.
Exclusion Criteria
  • Patients showing alarm symptoms (weight loss, anaemia, haematemesis, melaena, dysphagia, palpable abdominal mass) 2.
  • Having any systemic disease requiring long term treatment 3.
  • History of surgery related with the gastrointestinal tract more than six months 4.
  • Pregnancy and lactation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in signs and symptoms of Su’ al-Hadm (Dyspepsia)Six Weeks
Secondary Outcome Measures
NameTimeMethod
Haematological and biochemical assessment for safety assessmentInvestigations will be done at baseline and end of treatment

Trial Locations

Locations (3)

Central Research Institute of Unani Medicine (CRIUM)

🇮🇳

Lucknow, UTTAR PRADESH, India

Clinical Research Unit (CRU), Meerut

🇮🇳

Meerut, UTTAR PRADESH, India

Regional Research Institute of Unani Medicine (RRIUM)

🇮🇳

Delhi, DELHI, India

Central Research Institute of Unani Medicine (CRIUM)
🇮🇳Lucknow, UTTAR PRADESH, India
Dr Ziaul Haq Siddiqui
Principal investigator
9450655974
crium_lko@yahoo.co.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.